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Background: Acute heart failure (AHF) is a significant clinical problem, which has a high prevalence, mortality, 
and rehospitalization. Congestion is critical in the pathogenesis of AHF, which is also a predictor of mortality and 
rehospitalization in patients with AHF.
Objective: Knowing the effect of adding a %Total body water  (TBW) test detected  by Bioimpedance Analysis to 
NT-proBNP as a short-term clinical outside predictor of patients with acute heart failure
Method: This research is an analytical observational study using prospective cohort methods. The research was 
conducted at Dr. Saiful Anwar Malang Hospital in January 2018-July 2019 with research subjects taken consecu-
tively against all AHF patients hospitalized at RSUD dr. Saiful Anwar Malang. The data were taken in the form of 
NT-proBNP value during mission and %TBW before the patient leaves the hospital detected with NICaS examina-
tion. 90 days follow-up was conducted via phone calls to the patients, to evaluate the patient’s follow-up for 
cardiovascular death and rehospitalization.
Results:  This study involved 65 subjects who were on average 61 years old and the majority male. Non-survivor 
patients had a higher NYHA class, NT-proBNP, and %TBW pre-discharge than the survivor group. Based on a 
statistical analysis we found that the ROC curve shows NT-proBNP is a good predictor of mortality (HR: AUC 
0.74; 95%CI 0.59-0.90) and rehospitalization (HI: AUC 0.88; 95%CI 0.78-0.97). Similarly , %TBW pre-discharge 
shows good predictors of mortality (HI: AUC 0.72, 95%CI 0.56-0.87) and rehospitalization (HI: AUC 0.83, 95%CI 
0.73-0.94). The addition of the %TBW pre-discharge parameter to NT-proBNP results in the best predictor 
numbers among the three for both mortality (HI: AUC 0.84; 95%CI 0.72-0.96) and rehospitalization (HI: AUC 
0.92; 95%CI 0.85-1.00).
Conclusion: The addition of pre-discharge %TBW examination detected by a bioimpedance analysis tool to 
NT-pro BNP at admission, increases the predicted value of short-term clinical outpatient in the form of mortality 






 Acute heart failure (AHF) is a serious clinical problem that 
has led the patient to seek acute care and requiring urgent diagnosis, 
facilitating a treatment decision that is appropriate to the particular 
AHF mechanism.1 Furthermore, in-hospital mortality rates are higher 
after discharge, ranging from 4% to 8%, are estimated to be 8-15% by 
3 months, and are followed by regular rehospitalizations (30-38 
percent at 3 months).2,3
 The presence of signs and symptoms of systemic and pulmo-
nary congestion is the product of AHF clinical features.4 The main 
feature in the pathogenesis of AHF is congestion or fluid overload, and 
it is present in most patients admitted to this disease. Its severity was 
related to the prognosis of acute heart failure patients.5 Moreover, 
congestion is both a cause and an effect of worsening cardiovascular
function in heart failure. As a result of elevated ventricular wall 
tension, these pathophysiological alterations relate to clinical deteriora-
tion and brain natriuretic peptide (BNP) secretion.6 For all these 
concerns, in order to avoid this progressive hemodynamic pathway, 
AHF therapy is undertaken and, as a result, decongestion is an import-
ant priority in the care of these patients.7 Nearly half of hospitalized 
AHF patients, however, are discharged with chronic congestion signs 
and symptoms, and this is of considerable prognostic importance 
because the capacity to keep patient congestion-free will define a good 
survival population.8 The objective of this study is to investigate the 
additional prognostic power of combining congestion status detected 
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This is an observational analytic, with cohort prospective study. The 
sample of this study were patients with acute heart failure (AHF) presenting 
and admitted to Saiful Anwar General Hospital Malang. The inclusion criteria 
were: patients with age > 40 years old, who admitted with dyspnea due to AHF 
or symptoms linked to AHF, with hospitalization predicted. According to 
European Society of Cardiology standards, each patient got routine treatment 
and BIA values were blinded to the physicians. Exclusion criteria were pregnan-
cy, acute coronary syndrome, congenital heart disease, the patient experienced 
cardiac arrest, patient with stenotic valve disease, or prosthetic valve, COPD, 
pneumothorax, patient with malignancy or terminally ill with life expectancy 
less than 6 months, and patients who were discharged without beta-blockers or 
ACE inhibitor. The final diagnosis of AHF was made according to the recent 
guideline. Upon arrival at the ED, a blood examination for NT-proBNP was 
carried out for every patient. After that, the sample was sent to the central 
laboratory and was analyzed with a sandwich-type electrochemiluminescence 
sensor. We used a bioelectrical impedance analyzer, to analyze the percentage 
of total body water (TBW) of the patients, at the time before discharge (pre-dis-
charge). TBW was measured non-invasively using NICaS (Non-Invasive Cardiac 
System, Ni Medical Ltd., Singapore), bedside at supine position Without 
contact with metal and with abducted inferior limbs at 45 degrees and with 
abducted superior limbs at 30 degrees to prevent contact with the flesh. A 
phone call follow-up was conducted 90 days after hospital discharge to assess 
the follow-up of the patient for coronary mortality and rehospitalization.
2.2 Statistical Analysis
 Data were analyzed with SPSS 22 Software. Univariate 
analysis was performed for baseline characteristics. A bivariate analysis 
differences in medical therapy during hospitalization between survivors 
and non-survivors. All patients were discharged without any sign of 
clinical congestion.
 From the univariate analysis, NYHA, serum creatinine, rales, 
percentage TBW at discharge, and NT-proBNP admission are signifi-
cantly associated with 90 days mortality and rehospitalization. At 
multiple regression analysis, only NT-proBNP admission and percent-
age TBW predischarge maintain statistical significance (Table. 3). ROC 
analysis shows that percentage TBW pre-discharge is a predictor of 
death and rehospitalization (respectively, AUC : 0.72, 95% CI 0.56 – 
0.87.5 p<0.001 and AUC: 0.83, 95% CI 0.726 – 0.940 p<0.001). 
NT-proBNP also shown to be a predictor of death and rehospitalization 
from ROC analysis (respectively AUC: 0.74, 95% CI 0.586 – 0.893, p< 
0.001 and AUC: 0.88, 95% CI 0.784 – 0.972 p< 0.001). However,com-
bining percentage of TBW predischarge to NT-proBNP admission show 
the best prognostic value for mortality and rehospitalization (respec-
tively, AUC : 0.84, 95% CI 0.72 – 0.96 p<0.001 and AUC: 0.92, 95% CI 
0.85 - 1.00 p<0.001). The combination of these two shows better 
prognostic power compared to each parameter alone.
4. Discussion 
 Both BIA and BNP are presently used as valid methods for 
managing patients with AHF.9,10  Two facets of the same pathophysio-
logical pathway are reflected: BNP is released due to elevated 
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Table 1. Baseline characteristics of patients with 90 days mortality. 





Age (years), mean + SD 60.6±11.8 61.6±12.1 0.79 
Male (%) 66.7 58.5 0.60 
Orthopnea 93.3%(11/12) 94.3%(50/53) 0.27 
PND 66.7%(8/12) 69.8%(37/53) 0.83 
NYHA IV 71,4% 35,3 0.03 
SBP mmHg, mean + SD 136.4±26.4 141.8±33.2 0.60 
DBP mmHg, mean + SD 83.66±19.9 84.05±14.6 0.93 
MAP mmHg, mean + SD 101.2±20.8 103.3±19.8 0.74 
SaO2 %, mean + SD 97.3±1.6 97.0±1.4 0.65 
JVP cmH2O, mean + SD 9.2±1.0 9.1±0.96 0.70 
Rales 57.1% 15.7% 0.005 
S3 (%) 20% 28.8% 0.78 
Ascites (%) 20.0% 28.8% 0,78 
Leg Edema  (%) 12 (80.0%) 41 (87.2%) 0.78 
Atrial fibrillation (%) 20.0%(3) 12.8%(6) 0.78 
CTR %, mean + SD 72.94±5.95 69.71±4.82 0.31 
Alveolar congestion (%) 33.3% 29.8% 0.91 
Pleural Effusion (%) 20% 28.8% 0.78 
EF biplane %, mean + SD 41.4±11.2 40.0±13.3 0.72 
%TBW discharge 80.9±11.4 57.1±14.6 0.000 
NT-proBNP on admission 
pg/ml, mean + SD 
14210±1237 5075±740 0.015 
Sodium 138.4±3.9 138.2±4.0 0.88 
Potassium 3.9±0.4 4.0±0.7 0.63 
Kreatinin mg/dl, (>1.6 
mg/dl) (%) 
57% 21,6% 0.024 
eGFR (ml/menit/1.73 m2, 
mean + SD 
73.6±17.7 72.5±25.8 0.89 
Hemoglobin g/dl, mean + 12.5±2.0 13.6±1.7 0.37 
P.A. Kamila, et al.
Table 2. Patients condition and treatment at pre-discharge
  Non Survivor Survivor p 
n = 12 n = 53 
Dispnea (%) 0% 0% - 
Ortopnea (%) 0% 0% - 
PND (%) 0% 0% - 
GCS, mean + SD 15.00±0.00 15.00±0.00 1 
SBP mmHg, mean + SD 122.40±14.72 120.22±12.81 0.52 
DBP mmHg, mean + SD 72.35±12.83 70.49±8.20 0.68 
MAP mmHg, mean + SD 89.62±11.41 85.19±7.35 0.15 
HR x/minute, mean + 
SD 
76.7±2.38 76.94±6.22 0.94 
RR x/minute, mean + SD 19.71±1.06 19.36±0.93 0.25 
S3 (%) 0% 0% - 
Rhales (%) 0% 0% - 
JVP cmH2O, mean + SD 6.24±0.23 5.94±0.62 0.52 
Ascites (%) 0% 0% - 
Hepatomegaly (%) 0% 0% - 
Leg Edema (%) 0% 0% - 
Diuretic (%) 14(93.3%) 46(97.9%) 0.38 
Nitrat (%) 8(50%) 6(35.3%) 0.393 
Optimal ACEi/ARB (%) 13(86.7%) 33(70.2%) 0.20 
CCB (%) 21.4% 22.2% 0.95 
MRA (%) 42.9% 51.1% 0.59 
OAC/NOAC (%) 28.6% 13.3% 0.18 
Antiplatelet (%) 78.6% 62.2% 0.78 
Statin (%) 85.7% 68.9% 0.21 
β-blocker (%) 15(100%)` 47(100%) - 
Digoxin (%) 26.7% 11.1% 0.144 
Bisoprolol (mg) 2.5±0.0 2.52±0.0 0.92 
Furosemide (mg) 22.5±16.6 23.72±19.6 0.86 
Ramipril (mg) 10.0±0.0 9.36±0.3 0.41 
Table. 3. Multivariate Analysis
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percentage TBW at discharge, and NT-proBNP admission are signifi-
cantly associated with 90 days mortality and rehospitalization. At 
multiple regression analysis, only NT-proBNP admission and percent-
age TBW predischarge maintain statistical significance (Table. 3). ROC 
analysis shows that percentage TBW pre-discharge is a predictor of 
death and rehospitalization (respectively, AUC : 0.72, 95% CI 0.56 – 
0.87.5 p<0.001 and AUC: 0.83, 95% CI 0.726 – 0.940 p<0.001). 
NT-proBNP also shown to be a predictor of death and rehospitalization 
from ROC analysis (respectively AUC: 0.74, 95% CI 0.586 – 0.893, p< 
0.001 and AUC: 0.88, 95% CI 0.784 – 0.972 p< 0.001). However,com-
bining percentage of TBW predischarge to NT-proBNP admission show 
the best prognostic value for mortality and rehospitalization (respec-
tively, AUC : 0.84, 95% CI 0.72 – 0.96 p<0.001 and AUC: 0.92, 95% CI 
0.85 - 1.00 p<0.001). The combination of these two shows better 
prognostic power compared to each parameter alone.
4. Discussion 
 Both BIA and BNP are presently used as valid methods for 
managing patients with AHF.9,10 Two facets of the same 
differences in medical therapy during hospitalization between survivors 
and non-survivors. All patients were discharged without any sign of 
clinical congestiton.
 From the univariate analysis, NYHA, serum creatinine, rales, 
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Table 1. Baseline characteristics of patients with 90 days mortality. 
 
OR Sig 
TBW % pre-discharge 4.230 0.049 
NT-proBNP admission 5.817 0.010 
NT-proBNP admission + 
TBW % pre-discharge 
10.23 0.005 
NYHA Class IV 1.2 0.213 
Rales 1.2 0.499 
Creatinine Serum 2.09 0.899 
Figure 1  (A) ROC curve of NT-proBNP at admission to 90 days mortality. (B) ROC curve of NT-proBNP at admission to 90 days rehospitalization
Figure 2. A) ROC curve of pre-discharge %TBW to 90 days mortality. (B). ROC curve of pre-discharge %TBW to 90 days rehospitalization
(A) (B)
(A) (B)
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pathophysiological pathway are reflected: BNP is released due to 
elevated ventricular filling pressure and wall tension, while BIA 
variables reflect changes in body hydration of the failing cardiovascular 
system.11 BNPs alone, however, may not indicate pathophysiological 
congestion mechanisms, and other congestion indicators can be useful 
in determining congestion and risk stratification in patients with HF. 
BIA is a quick and easy tool for the evaluation of body peripheral 
hydration status among emerging strategies, offering prognostic 
information in HF patients.12,13
 A recent study has shown that bioimpedance analysis 
expressed in hydration status or total body water was related to 
NT-proBNP and CVP.14 In a recent analysis of the literature, Oremus et 
al. indicate that NT-proBNP in both decompensated and chronic 
healthy HF populations is correlated with all-cause mortality and 
composite outcome.6 There is, however, insufficient evidence in the 
literature that NT-proBNP contributes incremental importance to other 
prognostic variables in the short and long-term estimation of all-cause 
and cardiovascular mortality.15 Instead, when used in conjunction with 
BIA, NT-proBNP was more predictive of death and rehospitalization in 
our study. As for BIA variables at discharge, our analysis shows that 
with a chronic state of congestion, certain HF patients are discharged. 
Their detection is important since these patients are those at increased 
risk of death and rehospitalization for 90 days.16
 The role of BIA in detecting congestion and latent fluid 
overload, Valle et.al showed that it has better diagnostic sensitivity 
compared to other parameters such as fluid balance, and It also demon-
strates an emerging role in the prognostic significance.17 A previous 
study by Santarelli et.al indicates that the elimination of congestion 
observed by BIA during hospitalization of AHF patients is correlated 
with an improvement in the outcome of patients. 14,18 Donner Alves et 
al., who identify incremental improvements in hydration status during 
diuretic treatment in hospitalized AHF patients, demonstrate the same 
outcome.19 Instead, BIA prognostic significance before discharge was 
measured in this study. It was performed taking into account that 
clinical symptoms of congestion are frequently absent at this point as a 
result of diuretic treatment, and clinical judgment may not be accurate.
 This study offers valuable knowledge from this point of view 
that BIA analysis is beneficial as it facilitates the detection of certain 
patients that have subclinical congestion, and this could aid doctors in 
determining the discharge of the patient. Moreover, our findings 
support the effectiveness of BNP in the risk stratification of patients 
who presented to ED with AHF, but the most crucial and newest 
element is obtained from the combined use of NT-proBNP and BIA.
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The previous study shows NT-proBNP and BIA can be very helpful in 
the diagnosis, but also the clinical care of patients with AHF. This 
research expands these results, showing that they would have a poorer 
result when AHF patients are discharged with a chronic congestive 
state, even if clinically latent.18
 The limitations of this study are the sample size due to only 
a single center was involved in our study and the period of follow-up 
was quite short to rule-out biases. 
Conclusion
 Our study shows that in AHF patients, adding hydration 
status, measured as a percentage of total body water by bioimpedance 
analysis device before hospital discharge, to admission NT-proBNP 
increases short-term prediction for mortality and rehospitalization in 
acute heart failure patients.
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